Fauci you, Moderna! #DeanSays #SpikeProteins #COVID #Vaccines #Myocarditis #Celia #Purple #Supermodel Fight back with Spike Protein Detox: Now that that’s solved. What do we do about all those pesky little nanobots?

In a historic medical milestone, the world’s first mRNA-based lung cancer vaccine, BNT116, has entered human clinical trials across seven countries. Developed by BioNTech, the same company behind one of the leading COVID-19 vaccines, this breakthrough treatment targets non-small cell lung cancer (NSCLC) — the most common and deadliest type of lung cancer. The vaccine is designed to train the immune system to recognize and destroy cancer cells, offering a more targeted and less toxic alternative to conventional therapies. Currently in Phase 1 clinical trials, the vaccine is being tested on about 130 patients, including participants in the UK, Germany, Spain, and the U.S. The early-stage trials aim to assess safety and immune response, with hopes of preventing cancer recurrence in previously treated patients. If successful, BNT116 could revolutionize how we approach lung cancer — shifting treatment from chemotherapy to a personalized, immune-driven solution. The race toward a cancer vaccine future is officially underway. #LungCancerVaccine #BioNTech #CancerResearch #mRNAtechnology #CancerBreakthrough

The world’s first lung cancer vaccine, known as CIMAvax-EGF, has entered clinical trials in seven countries, marking a major milestone in cancer treatment. Unlike preventive vaccines, this is a therapeutic vaccine designed to treat existing lung cancer by targeting and neutralizing epidermal growth factor (EGF) — a protein that promotes the growth of cancer cells. Developed in Cuba, the vaccine has already shown promising results in extending survival for patients with advanced non-small cell lung cancer (NSCLC). Now, international clinical trials are being launched in the United States, United Kingdom, Japan, Cuba, Serbia, Bosnia and Herzegovina, and Colombia. The U.S. trials are being led by Roswell Park Comprehensive Cancer Center in partnership with Cuban researchers. This groundbreaking collaboration could offer a new path forward in cancer immunotherapy, particularly for one of the deadliest cancers globally. If successful, the vaccine may significantly improve outcomes and quality of life for lung cancer patients around the world.

Tuberculosis has plagued humanity for centuries, killing more people each year than nearly any other infectious disease. But scientists may have finally turned the tide. A new mRNA vaccine, dubbed mRNACV2, has demonstrated strong effectiveness in preclinical trials—triggering a powerful immune response in mice and dramatically reducing the bacterial load in their lungs. This represents a major leap beyond the current BCG vaccine, which offers limited protection and hasn't changed much since its introduction in 1921. What makes this breakthrough especially significant is the use of mRNA technology—the same approach that powered COVID-19 vaccines. This marks the first time mRNA has shown such promise against a bacterial infection, not just viruses. With human trials now on the horizon, the medical community is hopeful that this could lead to a durable, global solution for TB—a disease that still kills over 1 million people annually despite being preventable and treatable. #mRNAVaccine #TBCure #MedicalBreakthrough #InfectiousDiseases #PublicHealthRevolution